Pavone-Macaluso M. Does family history influence the risk of prostatecancer? In: Murphy G, Khoury S, Chatelain C, Denis L. (Eds). ThirdInternational Symposium on Recent Advances in Urological Cancer.Diagnosis and Treatment, 1992 pp. 29-31, Paris, SCIShibata A, Wh<strong>it</strong>temore AS. Prostate cancer incidence and mortal<strong>it</strong>y in theUn<strong>it</strong>ed States and the Un<strong>it</strong>ed Kingdom. J Natl Cancer I 2001; 93: 1109-1110DIAGNOSI PRECOCE E SCREENINGBoccardo F, Ciatto S, Martorana G. Italian National ConsensusConference on Prostate Cancer Screening (Florence, May 17, 2003) -Final consensus document. Int J Biol Markers 2003; 18(4): 238-240Ciatto S. Screening for prostate cancer by PSA determination: a time forcaution. Int J Biol Markers 2000;15: 285-287de Koning HJ, Auvinen A, Berenger-Sanchez A, Calais da Silva F, CiattoS, Denis L, Gohagan JK, Hakama M, Hugosson J, Kranse R, Nelen V,Prorok P, Schroeder F. <strong>La</strong>rge scale randomized prostate cancer screeningtrias: program performances in the european randomized screening forprostate cancer trial and the prostate, lung, colorectal and ovary cancertrial. Int J Cancer 2002; 97: 237-244Melia J and Moss S. Survey of the rate of PSA testing in general practice.Br<strong>it</strong> J Cancer 2001; 85: 656-665Advisory Comm<strong>it</strong>tee on Cancer Prevention. Pos<strong>it</strong>ion paper.Recommendations on cancer screening in European Union. Eur J Cancer2000; 36: 1473-1478SINTOMATOLOGIACarter HB et al. Report to the Nation on Prostate Cancer 2004.Prostate Cancer Foundation 2004Harrrison's "Principles of internal me<strong>di</strong>cine" 14th ed. Mc Graw Hill 1998CIDIMU (centro <strong>it</strong>aliano <strong>di</strong> <strong>di</strong>agnostica me<strong>di</strong>ca ultrasonica)AIMAC (associazione <strong>it</strong>aliana malati <strong>di</strong> cancro)J. Black et E. Matassarin Jacobs “Lukmann and Sorensen’s” IV e<strong>di</strong>zione;75: 2580-2591
DIAGNOSIBabaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D,Chen M. A comparative analysis of sextant and an extended 11-coremultis<strong>it</strong>e <strong>di</strong>rected biopsy strategy. J Urol 2000 Jan; 163 (1): 152-7Chiou RK, Anderson JC, Peckham JC, et al. Does color Doppler imagingcontribute to prostate cancer detection? Preliminary result of a urologistra<strong>di</strong>ologistcollaborative study. J Urol 2000; 163 (4): 280 [Abs 1245]Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeatprostate biopsy: Who, how and when? A review. Eur Urol 2002; 42: 93-103Brawer MK et al. Complexed prostate specific antigen provides significantenhancement of specific<strong>it</strong>y compared w<strong>it</strong>h total prostate specific antigenfor detecting prostate cancer. J Urol 2000; 163: 1476-80Levine MA, Ittman M, Melamed J. Two consecutive sets of transrectalultrasound guided sextant biopsies of the prostate for the detection ofprostate cancer. J Urol 1998; 159: 471Nasu Y, Saika T, Arata R, et al. The clinical value of contrast-enhancedcolor Doppler ultrasound: is <strong>it</strong> really useful in the <strong>di</strong>agnosis of prostatecancer? J Urol 2000;163 (4): 280 [Abs 1244]Vallancien G, Prapotnich D, Veillon B, et al. Systematic prostatic biopsiesin 100 men w<strong>it</strong>h no suspicion of cancer on <strong>di</strong>g<strong>it</strong>al rectal examination. JUrol 1991; 146: 1308Roerhborn CG, Pickers GJ, Sanders JS. Diagnostic yield of repeatedultrasound guided biopsies stratified by specific histopathologic <strong>di</strong>agnosisand prostate specific antigen levels. Urology 1996; 47: 347-352Kirollos MM. et al. Statistical review and analysis of the relationshipbetween serum prostate-specific antigen and age. J Urol 1997; 58 (1):143-145CENNI DI ANATOMIA PATOLOGICAAtlas of Tumor Pathology Tumors of the prostate gland, Seminal Vesicles,Male Urethra an Penis by R.H. Young J.R Srigley, M.B. Amin, T.M.Ulbright, A. Cubilla AFIP Washington D.C. 2000Hoedemaeker RF, Vis AN, Van der Kwast TH. Staging prostate cancer.Microsc Res Technique 2000; 51. 423-429
- Page 1 and 2:
UNIVERSITA’ DEGLI STUDI DI TORINO
- Page 3 and 4:
Prostatectomia RadicaleProstatectom
- Page 5 and 6:
Il rischio cumulativo di ammalarsi
- Page 7 and 8:
significative che sembrerebbero avv
- Page 9 and 10:
Purtroppo alcune autorevoli associa
- Page 11 and 12:
SINTOMATOLOGIAPremesso che il carci
- Page 13 and 14:
Con la DRE si apprezzano il tono de
- Page 15 and 16:
giunte alla fase sintomatica, né t
- Page 17 and 18:
Tuttavia, solo il PSA prodotto dall
- Page 19 and 20:
flogosi acuta, infarti, piccoli nod
- Page 21 and 22:
La scelta dell'ago da utilizzare va
- Page 23 and 24:
In tali casi sia lo stadio che lo s
- Page 25 and 26:
PSA T = Antigene Prostatico Specifi
- Page 27 and 28:
ClinicaNX I linfonodi regionali non
- Page 29 and 30:
dimensioni o volume della neoplasia
- Page 31 and 32:
In una minoranza di casi, il tumore
- Page 33 and 34:
APPROCCIO TERAPEUTICOBRACHITERAPIA1
- Page 35 and 36:
All'interno della ghiandola prostat
- Page 37 and 38:
Nodulo (T2a)Al di là delle indicaz
- Page 39 and 40:
volume della ghiandola prostatica;
- Page 41 and 42:
Si posiziona infine temporaneamente
- Page 43 and 44: Circa 3 settimane dopo l'impianto d
- Page 45 and 46: durante le otto settimane (Pd-103)
- Page 47 and 48: RADIOTERAPIA1 Radioterapia radicale
- Page 49 and 50: Le eventuali tossicità tardive son
- Page 51 and 52: dimostrano che la soppressione ormo
- Page 53 and 54: La dose totale suggerita è di 60-6
- Page 55 and 56: Sintomi neurologici causati da seco
- Page 57 and 58: Il trattamento può essere associat
- Page 59 and 60: Il tasso di mortalità peri-operato
- Page 61 and 62: PazientiHan, 2003 2,091 84% 72% 61%
- Page 63 and 64: COMPLICANZELa maggior parte dei paz
- Page 65 and 66: Si preferisce usare un’anestesia
- Page 67 and 68: ALTRE OPZIONI TERAPEUTICHE1. CRIOTE
- Page 69 and 70: ghiaccio non interessa adeguatament
- Page 71 and 72: L'impiego di efficaci dispositivi d
- Page 73 and 74: Shinohara e coll. hanno rilevato ch
- Page 75 and 76: Al di fuori dell'area focale, l'int
- Page 77 and 78: Su oltre 4000 pazienti, trattati a
- Page 79 and 80: L'utilizzo delle radiofrequenze si
- Page 81 and 82: L’utilizzo del questionario sotto
- Page 83: NDE8B 2 23 428C 1 7 24 358D 1 9 15
- Page 86 and 87: 6 a1019%6 b504030201069%160%01 2 3
- Page 88 and 89: Professionalità11%710%1053%936%Anc
- Page 90 and 91: 60509 a9 b11%53%63% 84%403020101083
- Page 92 and 93: delle sue possibilità nei confront
- Page 96 and 97: Kunz G, Epstein JI: Should each cor
- Page 98: Megalli MR, Gursel EO, Veenema RJ.